Latest Articles
Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma - springermedicine.com
Mendelian randomization analysis of PKD1 in endometrial cancer and comparative multi-cancer study with renal cell carcinoma springermedicine.com
Published: Jan. 14, 2026, 6:02 a.m.
Scientists warn spraying perfume on neck may disrupt hormones and thyroid function - The Eastleigh Voice
Scientists warn spraying perfume on neck may disrupt hormones and thyroid function The Eastleigh Voice
Published: Jan. 14, 2026, 5:07 a.m.
ASCO 2025: key highlights in endometrial cancer - springermedicine.com
ASCO 2025: key highlights in endometrial cancer springermedicine.com
Published: Jan. 13, 2026, 5:23 a.m.
Integrating IVF and Surgical Management in Endometriosis-Associated Infertility: A Review - springermedicine.com
Integrating IVF and Surgical Management in Endometriosis-Associated Infertility: A Review springermedicine.com
Published: Jan. 13, 2026, 5:03 a.m.
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer - The ASCO Post
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer The ASCO Post
Published: Jan. 12, 2026, 6:10 p.m.
Single hormone shot kept levels low for weeks with no short-term bone loss - Stock Titan
Single hormone shot kept levels low for weeks with no short-term bone loss Stock Titan
Published: Jan. 12, 2026, 12:30 p.m.
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women - GlobeNewswire
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women GlobeNewswire
Published: Jan. 12, 2026, 12:30 p.m.
Woman told 'pain is normal' for five years before getting life-changing diagnosis - MSN
Woman told 'pain is normal' for five years before getting life-changing diagnosis MSN
Published: Jan. 11, 2026, 7:32 a.m.
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - Defense World
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan Defense World
Published: Jan. 10, 2026, 6:12 a.m.
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - ETPharma.com
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty ETPharma.com
Published: Jan. 10, 2026, 1:55 a.m.
Link copied to clipboard!